Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q1 FY20
Investor Presentation
Q4 FY19
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
943.65 | 5,444 Cr | 38.63 | 4.99 | 0.21 | 12.92 | 14.30 | 7.67 | ||
1159.60 | 5,340 Cr | 46.29 | 5.72 | 0.00 | 12.36 | 14.43 | 7.58 | ||
436.05 | 4,613 Cr | 35.72 | 3.87 | 0.23 | 10.82 | 16.48 | 9.03 | ||
835.80 | 4,324 Cr | 212.36 | 3.36 | 0.00 | 2.11 | 2.48 | 1.10 | ||
378.40 | 4,162 Cr | 89.19 | 14.46 | 0.18 | 16.22 | 14.47 | 9.27 | ||
1196.60 | 4,144 Cr | -56.05 | 5.98 | 0.08 | -10.66 | -6.48 | -6.55 | ||
128.35 | 3,753 Cr | 27.26 | 2.09 | 0.78 | 7.65 | 10.29 | 5.32 | ||
| Median: 7 Co. | — | 835.80 | 4,324 Cr | 38.63 | 4.99 | 0.18 | 10.82 | 14.30 | 7.58 |
Bliss GVS Pharma Ltd (BLISSGVS) is currently trading at 440.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries. The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa. Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations. Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum. Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.
Over the past 52 weeks, Bliss GVS Pharma Ltd has traded between a low of ₹118.35 and a high of ₹462.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Bliss GVS Pharma Ltd has a market capitalization of approximately 4,612.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Bliss GVS Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.72 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,612.93 Cr, Bliss GVS Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Bliss GVS Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Bliss GVS Pharma Ltd is 35.72. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock surged after Anupam Rasayan announced a plan to acquire up to a 43.3% stake in Bliss GVS Pharma, triggering strong buying interest.
The stock surged after Bliss GVS Pharma said Anupam Rasayan would acquire about 43% stake for ₹1,369.51 crore, triggering a mandatory open offer.
The stock hit the 20% upper circuit after Anupam Rasayan India announced plans to acquire up to 43.3% stake in Bliss GVS Pharma and launch an open offer.
Anupam Rasayan said it will acquire a 43.3% stake in Bliss GVS Pharma, and also mentioned a definitive agreement to acquire a 43.3-48.2% equity stake.
Open Offer / Takeover
Bliss GVS Pharma received and filed the Draft Letter of Offer (DLOF) with SEBI for an open offer by Anupam Rasayan India Ltd. to acquire up to 2,77,26,848 shares (26% of expanded voting capital) at ₹299 per share via SBI Cap.
Open Offer Filing
Bliss GVS Pharma received and submitted to SEBI a Draft Letter of Offer from SBI Capital Markets for Anupam Rasayan’s open offer to acquire up to 27,726,848 shares (26% of expanded voting capital) at ₹299 per share.
Open Offer / Takeover
Anupam Rasayan India Ltd has submitted a Draft Letter of Offer (dated June 08, 2026) to acquire up to 2,77,26,848 equity shares (26.00% of expanded voting capital) of Bliss GVS Pharma Ltd at ₹299 per share via an open offer; SBI Capital Markets is the manager and MUFG Intime the registrar.
Open Offer
Draft Letter of Offer filed with BSE (dated June 08, 2026) for an open offer by Anupam Rasayan India Ltd to acquire up to 2,77,26,848 equity shares (26% of expanded voting capital) of Bliss GVS Pharma at ₹299/share.
Bearish
3
Neutral
5
Bullish
6
Bearish
4
Neutral
5
Bullish
37
Bearish
1
Neutral
0
Bullish
31
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries.
The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa.
Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations.
Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum.
Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,613 Cr
High Risk
35.7
34.1
3.3
3.9
462.70
118.35
Sales CAGR
Profit CAGR
ROE
ROCE
